TFB1M

Across TCGA pan-cancer cohorts, TFB1M Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFB1M data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TFB1M Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFB1M expression acts as an unfavorable survival marker.

LIHC, SKCM, and UCEC are the cancer types where TFB1M Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.118	0.544	.007	9	view →
SKCM	DFS	Median	All	0.224	0.623	.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	II,III,IV	0.545	0.677	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFB1M–LIHC (DFS)

Open the LIHC breakdown →